Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Buparlisib (Primary)
- Indications Urogenital cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 17 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.